• Monday, December 27, 2021 @ 12:00 pm

Nice & Green extends its support to the Swiss biotech Evolva with additional financing of CHF 12M

Nice & Green, the Swiss investment firm, commits to additional funding of CHF 12 million as part of its investment partnership with Evolva, the Swiss biotech company focused on the research, development and commercialization of products based on nature.

The extended agreement between Nice & Green and Evolva will be unfolded through the issuing of convertible notes under agreed-upon terms until the end of 2023. The total available funds to date – up to CHF 28 million – will allow Evolva to accelerate its growth and will be deployed to support its commercial operations and product launches in key markets, as well as to fund the further development of the company's product pipeline.

You may also be interested in